FIDAS-3 是一种二苯乙烯衍生物,也是一种强效的Wnt抑制剂,对甲硫氨酸腺苷转移酶 2A (MAT2A) 的IC50为 4.9 μM。FIDAS-3 与 S-腺苷甲硫氨酸 (SAM) 有效竞争MAT2A结合,并具有抗癌活性。
生物活性 | FIDAS-3 is a stilbene derivative and is a potentWntinhibitor with anIC50of 4.9 μM formethionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) forMAT2Abinding. FIDAS-3 has anticancer activities[1][2]. |
IC50& Target | IC50: 4.9 μM (Methionine S-adenosyltransferase 2A (MAT2A))[1] |
体外研究 (In Vitro) | FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells[1]. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21WAF1/CIP1[1]. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells[1].
Cell Viability Assay[1] Cell Line: | LS174T colorectal cancer (CRC) cells | Concentration: | 3 μM | Incubation Time: | 7 days | Result: | Significantly inhibited the proliferation of LS174T cells. |
|
体内研究 (In Vivo) | FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors[2].
Animal Model: | C57BL/6J athymic nude mice (6-8 week) injected with LS174 cells[2] | Dosage: | 20 mg/kg | Administration: | Intraperitoneal injection; daily; for one months | Result: | Significantly inhibited the growth of xenograft tumors. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(385.67 mM;Need ultrasonic) 配制储备液 1 mM | 3.8567 mL | 19.2834 mL | 38.5669 mL | 5 mM | 0.7713 mL | 3.8567 mL | 7.7134 mL | 10 mM | 0.3857 mL | 1.9283 mL | 3.8567 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (9.64 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (9.64 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|